Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 21 to 64 Years of Age
NCT01934127
Completed
The purpose of this study is to evaluate the safety and immunogenicity of different formulations of GSK Biologicals H7N1 influenza vaccine in subjects 21 to 64 years of age. The study will evaluate safety related events and antibody immune responses to different formulations of study vaccine and placebo.
Gender:
ALL
Ages:
Between 21 years and 64 years
Trial Updated:
05/04/2017
Locations: GSK Investigational Site, Miami, Florida +8 locations
Conditions: Influenza
Register for Updates
Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.
NCT02097849
Completed
Primary objective is to evaluate the immune response to vaccination with tetanus diphtheria toxoids vaccine (Td) in participants with relapsing forms of Multiple Sclerosis (MS) who have been treated with Tecfidera (BG00012) versus those treated with non pegylated interferon (IFN). Secondary objective is to evaluate the immune response to vaccination with 23-valent pneumococcal polysaccharide vaccine (PPSV23) \[a mostly T cell-independent humoral response\] and meningococcal polysaccharide dipht... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
05/01/2017
Locations: Research Site, Gilbert, Arizona +13 locations
Conditions: Relapsing Forms of Multiple Sclerosis
Register for Updates
Responses to Influenza Vaccine in Patients With Mitochondrial Disorders (MELAS)
NCT01831934
Completed
This pilot clinical study evaluated the safety and metabolic responses to a licensed inactivated seasonal influenza vaccine (TIV) in mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome (MELAS) volunteers and controls.
Gender:
ALL
Ages:
Between 13 years and 65 years
Trial Updated:
04/25/2017
Locations: Stanford University School of Medicine, Stanford, California
Conditions: MELAS Syndrome
Register for Updates
Evaluating the Safety and Immunogenicity of a H7N9 Vaccine for the Prevention of Influenza H7N9 Disease in Adults 50 to 70 Years Old
NCT02274545
Completed
H7N9 viruses have caused an outbreak of severe respiratory disease in 2013-2014 in China that affected many older adults. This study will evaluate the safety of and immune response to a live attenuated H7N9 vaccine in adults 50 to 70 years old.
Gender:
ALL
Ages:
Between 50 years and 70 years
Trial Updated:
04/18/2017
Locations: University of Rochester Medical Center, Rochester, New York
Conditions: Influenza A Virus, H7N9 Subtype
Register for Updates
A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine in a Pediatric Population
NCT00959049
Completed
The purpose of this study is to determine the immunogenicity and safety profile of CSL Limited's Influenza Virus Vaccine compared to a US licensed comparator Influenza Virus Vaccine in a pediatric population aged greater than or equal to 6 months to less than 18 years.
Gender:
ALL
Ages:
Between 6 months and 17 years
Trial Updated:
04/16/2017
Locations: Not set, Chandler, Arizona +22 locations
Conditions: Influenza
Register for Updates
An Intervention Study To Improve Human PapillomaVirus ( HPV) Immunization in Haitian and African American Girls
NCT01254669
Completed
In the United States, Black women are more likely to die of cervical cancer than White women. In developing countries and globally, Haitian immigrant women are more likely to die of cervical cancer than any other women in the world. Studies have shown a disparity in parental acceptance of the HPV vaccine with parents of Black adolescent girls being less likely to accept and comply with HPV immunization schedules than Whites. The objective of this study is to increase HPV immunization rates in Ha... Read More
Gender:
FEMALE
Ages:
Between 11 years and 15 years
Trial Updated:
04/11/2017
Locations: Boston Medical Center, Boston, Massachusetts
Conditions: Cervical Cancer
Register for Updates
TDENV PIV and LAV Dengue Prime-boost Strategy Using AS03B Adjuvant
NCT03110952
Withdrawn
The potential synergistic effect of administering 2 dengue vaccine candidates that were previously shown to be safe and immunogenic in humans will be evaluated in this study. A prime-boost study of tetravalent dengue virus purified inactivated vaccine (TDENV-PIV) with the GSK AS03B adjuvant and tetravalent dengue live attenuated virus (TDENV-LAV) vaccine Formulation 17 (F17) will gather data to help better understand the human immune response to dengue vaccination and infection. This study is b... Read More
Gender:
ALL
Ages:
Between 18 years and 39 years
Trial Updated:
04/05/2017
Locations: Upstate Medical University, SUNY, Syracuse, New York
Conditions: Dengue
Register for Updates
Trial to Evaluate Safety and Immunogenicity of an Ebola Zaire Vaccine in Healthy Adults
NCT02718469
Completed
The purpose of this study is to assess the safety profile of the Zaire Ebola vaccine and the strength of the immune response.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
04/03/2017
Locations: Optimal Research, Melbourne, Florida
Conditions: Ebola Virus Disease
Register for Updates
Safety of a Live Attenuated Human Parainfluenza Virus Type 2 (HPIV2) Vaccine for Adults, Children, and Infants
NCT01139437
Completed
Human parainfluenza virus type 2 (HPIV2) can result in severe respiratory illness in infants and young children. This study will test the safety of and immune response to an HPIV2 vaccine aimed at infants and children.
Gender:
ALL
Ages:
Between 6 months and 49 years
Trial Updated:
03/31/2017
Locations: Johns Hopkins University, Bloomberg School of Public Health, Baltimore, Maryland
Conditions: Human Parainfluenza Virus 2
Register for Updates
Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer
NCT00103116
Completed
RATIONALE: Vaccines made from a person's white blood cells and allogeneic tumor cells may make the body build an effective immune response to kill tumor cells. PURPOSE: This phase II trial is studying how well vaccine therapy works in treating patients with stage I, stage II, or stage III non-small cell lung cancer.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/30/2017
Locations: Markey Cancer Center at University of Kentucky Chandler Medical Center, Lexington, Kentucky
Conditions: Lung Cancer
Register for Updates
Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free
NCT01141491
Completed
Sarcoma patients are at high risk for their cancer to recur even when the sarcoma has been removed surgically or treated with radiation or chemotherapy. The patients in the study will be randomized (like flipping a coin) to receive either a vaccine that is combined with an immune system stimulant or the immune system stimulant alone. The immune system stimulant is called OPT-821 and is an immunological booster. The trivalent vaccine is being developed to teach the patient's immune system to reco... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
03/14/2017
Locations: UCLA Medical Center, Los Angeles, California +12 locations
Conditions: Sarcoma
Register for Updates
Tailoring of Vaccine-Focused Messages: Moral Foundations
NCT02851459
Completed
This study is the first phase of a trial examining decision making about vaccines. This phase tests the impact of targeted vaccine-focused health messages on vaccine beliefs held by parents of young children and pre-adolescents. The participant's vaccine beliefs will be assessed at baseline. Two weeks later, the participant's moral matrix will be assessed. A vaccine-related message that appeals to the individual's three most or least emphasized moral foundations will then be presented. Immediate... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
03/09/2017
Locations: Emory University School Of Public Health - Only Online Recruitment, Atlanta, Georgia
Conditions: Childhood Vaccinations
Register for Updates